Probing into 9’-substituted Suzuki-coupled noscapine ionic liquids as potent microtubule targeting anticancer agents with hemoglobin affinity

Uloženo v:
Podrobná bibliografie
Vydáno v:Scientific Reports (Nature Publisher Group) vol. 15, no. 1 (2025), p. 33734-33753
Hlavní autor: Sewariya, Shubham
Další autoři: Mishra, Nistha, Panchal, Sagar, Kukreti, Shrikant, Chandra, Ramesh
Vydáno:
Nature Publishing Group
Témata:
On-line přístup:Citation/Abstract
Full Text
Full Text - PDF
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

MARC

LEADER 00000nab a2200000uu 4500
001 3256003900
003 UK-CbPIL
022 |a 2045-2322 
024 7 |a 10.1038/s41598-025-94336-z  |2 doi 
035 |a 3256003900 
045 2 |b d20250101  |b d20251231 
084 |a 274855  |2 nlm 
100 1 |a Sewariya, Shubham  |u Department of Chemistry, University of Delhi, 110007, Delhi, India (ROR: https://ror.org/04gzb2213) (GRID: grid.8195.5) (ISNI: 0000 0001 2109 4999); School of Pharmacy and Biomedical Sciences, University of Central Lancashire, PR1 7QT, Preston, UK (ROR: https://ror.org/010jbqd54) (GRID: grid.7943.9) (ISNI: 0000 0001 2167 3843); Maharaja Surajmal Brij University, 321201, Rajasthan, India 
245 1 |a Probing into 9’-substituted Suzuki-coupled noscapine ionic liquids as potent microtubule targeting anticancer agents with hemoglobin affinity 
260 |b Nature Publishing Group  |c 2025 
513 |a Journal Article 
520 3 |a On a global scale, lung cancer accounts for 18% of all cancer deaths making it the most lethal cancer. To restrain this, there has been continual research in the domain of microtubule-targeting anticancer agents but issues like toxicity, immunosuppression, effective delivery to tumor site, etc. persist to impede their clinical success. Unlike the other existing drugs in this regime; noscapine (a non-opioid alkaloid) is testified to be an intrinsically safer drug with minimal side effects. In this work, we have synthesized and evaluated novel 9’-substituted suzuki-coupled noscapine ionic liquid(s) as effectual anticancer drug(s) against non-small cell (H1299) lung cancer. We have devised a synthetic route (employed suzuki coupling for subsuming the biaryl pharmacophore and combined it with the idea of active pharmaceutical ingredient-based ionic liquids (API-ILs)) to yield the desired API-ILs followed by their characterization using associated analytical techniques like NMR, HRMS, etc. Following this, we have performed SAR analysis of the API-ILs using molecular docking with the target tubulin protein and preliminary in vitro screening against H1299 (non-small cancer) cells to opt for the most promising analogue i.e., [p-NO2-Nos]I. Upon finding the most potent ionic liquid, we carried out MD simulations and MM-PBSA/GBSA calculations to get an insight into its interaction with tubulin and human hemoglobin using computational and spectroscopic studies respectively. From computational studies, we inferred that [p-NO2-Nos]I forms a stable complex with tubulin mainly driven by non-polar interactions. From spectroscopic studies, we disclosed that [p-NO2-Nos]I binds to human hemoglobin (Hb) in a 1:1 stoichiometric ratio with a binding constant (Kb) of ~ 1.38 × 105 M−1 at 298 K. Finally, we have examined the cytotoxicity of [p-NO2-Nos]I against H1299 cancer cell line and compared it to [9-Br-Nos]IBr2, noscapine and Paclitaxel. The IC50 values for [p-NO2-Nos]I came out to be 67.84 ± 4.84 µM at 48 h and 19.67 ± 3.1µM at 72 h, both of which were significantly lower than [9-Br-Nos]IBr2 and Noscapine. The potent [p-NO2-Nos]I was further screened using A549 cell line and similar results were observed relative to H1299 cell line. Overall, these findings envelop the potential of such enhanced spindle poisons against lung cancer. 
653 |a Cytotoxicity 
653 |a Side effects 
653 |a Hemoglobin 
653 |a Lung cancer 
653 |a Nitrogen dioxide 
653 |a Solvents 
653 |a Immunosuppression 
653 |a Antineoplastic drugs 
653 |a Paclitaxel 
653 |a Drugs 
653 |a Tubulin 
653 |a Computer applications 
653 |a Immunosuppressive agents 
653 |a Chromatography 
653 |a Poisons 
653 |a Environmental 
700 1 |a Mishra, Nistha  |u Department of Chemistry, University of Delhi, 110007, Delhi, India (ROR: https://ror.org/04gzb2213) (GRID: grid.8195.5) (ISNI: 0000 0001 2109 4999); Department of Biotechnology, Delhi Technological University, 110042, Delhi, India (ROR: https://ror.org/01ztcvt22) (GRID: grid.440678.9) (ISNI: 0000 0001 0674 5044) 
700 1 |a Panchal, Sagar  |u Department of Chemistry, University of Delhi, 110007, Delhi, India (ROR: https://ror.org/04gzb2213) (GRID: grid.8195.5) (ISNI: 0000 0001 2109 4999) 
700 1 |a Kukreti, Shrikant  |u Department of Chemistry, University of Delhi, 110007, Delhi, India (ROR: https://ror.org/04gzb2213) (GRID: grid.8195.5) (ISNI: 0000 0001 2109 4999) 
700 1 |a Chandra, Ramesh  |u Department of Chemistry, University of Delhi, 110007, Delhi, India (ROR: https://ror.org/04gzb2213) (GRID: grid.8195.5) (ISNI: 0000 0001 2109 4999); Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, 110007, Delhi, India (ROR: https://ror.org/04gzb2213) (GRID: grid.8195.5) (ISNI: 0000 0001 2109 4999); Institute of Nano Medical Sciences, University of Delhi, 110007, Delhi, India (ROR: https://ror.org/04gzb2213) (GRID: grid.8195.5) (ISNI: 0000 0001 2109 4999); Maharaja Surajmal Brij University, 321201, Rajasthan, India 
773 0 |t Scientific Reports (Nature Publisher Group)  |g vol. 15, no. 1 (2025), p. 33734-33753 
786 0 |d ProQuest  |t Science Database 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3256003900/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/3256003900/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3256003900/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch